Table 1.

Clinical and Molecular Characteristics According to CEBPA Mutational Status in Cytogenetically Normal Acute Myeloid Leukemia Patients

Characteristic	Mutated CEBPA (n = 32)		Wild-Type CEBPA (n = 143)		P
	No. of Patients	%	No. of Patients	%
Age, years					.69
Median	44		46
Range	19-59		18-59
Male	18	56	67	47	.43
Race					1.00
White	29	91	126	89
Nonwhite	3	9	16	11
Hemoglobin, g/dL					.02
Median	10.1		9.4
Range	4.9-13.4		4.8-13.6
Platelet count, × 109/L					.009
Median	38		61
Range	7-232		11-445
WBC, × 109/L					.17
Median	19.1		30.2
Range	4.9-295.0		1.4-273.0
% of blood blasts					.07
Median	64.5		58
Range	10-97		0-95
% of bone marrow blasts					.15
Median	61.5		70
Range	26-98		10-99
Extramedullary disease	5	16	50	35	.03
FLT3-ITD					.07
Negative	24	75	81	57
Positive	8	25	62	43
NPM1					< .0001
Wild type	26	81	32	22
Mutated	6	19	111	78
Molecular risk group*					< .001
Low risk	3	9	57	40
High risk	29	91	86	60
FLT3-TKD					.20
Negative	31	97	125	88
Positive	1	3	17	12
MLL-PTD					.26
Negative	28	88	134	94
Positive	4	12	9	6
WT1					.25
Wild type	26	81	119	89
Mutated	6	19	15	11
BAALC expression†					.003
Low	7	24	58	55
High	22	76	47	45
Unkown	3		38
ERG expression‡					.26
Low	19	73	62	59
High	7	27	43	41
Unknown	6		38

Abbreviations: FLT3-ITD, internal tandem duplication of the FLT3 gene; FLT3-TKD, tyrosine kinase domain mutations of the FLT3 gene; MLL-PTD, partial tandem duplication of the MLL gene.

^*Molecular low-risk group is defined by the absence of FLT3-ITD and presence of NPM1 mutation. Molecular high-risk group is defined by the presence of FLT3-ITD and/or the lack of NPM1 mutation.

^†BAALC expression values were dichotomized at the median to define high and low expressers.

^‡ERG expression values were dichotomized at the median (Cancer and Leukemia Group B 19808 trial)¹³ or at the 75th percentile (Cancer and Leukemia Group B 9621 trial)¹² to define high and low expressers.